October 16, 2024 03:19 PM EDT

Compounding association to ask for clarity around tirzepatide's shortage status

Nicole DeFeudis

Editor

The Alliance for Pharmacy Compounding (APC) wants clarity around the FDA’s decision to reconsider tirzepatide’s removal from its national shortage list.

Compounders are allowed to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Compounding association to ask for clarity around tirzepatide's shortage status

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

First clinical test of RNA editing restores missing protein in genetic disease, Wave says

FDA leaders kick off rare disease hub to increase cross-center collaboration

Facing a critical week, Pfizer confronts an unsparing foe in Starboard

FDA places hold on Novavax's Covid-flu and standalone influenza vaccines

Q&A: Sanofi’s R&D head reflects on his first year, a post-Dupixent future, and finding an identity

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

Com­pound­ing as­so­ci­a­tion to ask for clar­i­ty around tirzepatide's short­age sta­tus

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Compounding association to ask for clarity around tirzepatide's shortage status